Cetuximab

被引：134

作者：

Graham, J ^{[1
]}

Muhsin, M ^{[1
]}

Kirkpatrick, P ^{[1
]}

机构：

[1] Decis Resources Int, London WC1B 4HQ, England

来源：

NATURE REVIEWS DRUG DISCOVERY | 2004年 / 3卷 / 07期

关键词：

D O I：

10.1038/nrd1445

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Cetuximab (Erbitux; ImClone Systems/Bristol-Myers Squibb) is a monoclonal antibody that binds to the epidermal growth factor receptor, which is important in the growth of many cancers. In February 2004, it was granted accelerated approval by the FDA for the treatment of metastatic colorectal cancer on the basis of tumour response rates in Phase II trials.

引用

页码：549 / 550

页数：2

共 9 条

[1] Baselga J, 2001, EUR J CANCER, V37, pS16
[2] BURTNESS BA, 2002, P AN M AM SOC CLIN, V21, pA226
[3] Cytotoxic and molecular-targeted therapies of head and neck tumors
Caponigro, F
Ionna, F
Comella, G
[J]. CURRENT OPINION IN ONCOLOGY, 2004, 16 (03) : 225 - 230
[4] Issues and progress with protein kinase inhibitors for cancer treatment
Dancey, J
Sausville, EA
[J]. NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (04) : 296 - 313
[5] Goldstein NI, 1995, CLIN CANCER RES, V1, P1311
[6] Parkin DM, 2001, EUR J CANCER, V37, pS4, DOI 10.1016/S0959-8049(01)00267-2
[7] Prewett MC, 2002, CLIN CANCER RES, V8, P994
[8] EPIDERMAL GROWTH FACTOR-RELATED PEPTIDES AND THEIR RECEPTORS IN HUMAN MALIGNANCIES
SALOMON, DS
BRANDT, R
CIARDIELLO, F
NORMANNO, N
[J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 1995, 19 (03) : 183 - 232
[9] Untangling the ErbB signalling network
Yarden, Y
Sliwkowski, MX
[J]. NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2001, 2 (02) : 127 - 137

← 1 →